Zacks: Analysts Anticipate Supernus Pharmaceuticals, Inc. (SUPN) Will Announce Quarterly Sales of $86.59 Million

Brokerages predict that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will report $86.59 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Supernus Pharmaceuticals’ earnings, with estimates ranging from $81.33 million to $92.17 million. Supernus Pharmaceuticals posted sales of $62.37 million in the same quarter last year, which suggests a positive year over year growth rate of 38.8%. The business is scheduled to report its next earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year sales of $86.59 million for the current fiscal year, with estimates ranging from $297.95 million to $305.98 million. For the next fiscal year, analysts expect that the business will report sales of $393.84 million per share, with estimates ranging from $385.13 million to $404.56 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. The firm’s revenue for the quarter was up 41.5% on a year-over-year basis.

SUPN has been the subject of a number of analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $51.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Stifel Nicolaus reaffirmed a “buy” rating and set a $47.00 price objective (up from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $49.00 price objective on shares of Supernus Pharmaceuticals in a report on Tuesday, September 19th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $50.00 price objective on shares of Supernus Pharmaceuticals in a report on Thursday, September 21st. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $49.60.

TRADEMARK VIOLATION NOTICE: This news story was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://stocknewstimes.com/2017/11/11/zacks-analysts-anticipate-supernus-pharmaceuticals-inc-supn-will-announce-quarterly-sales-of-86-59-million.html.

In related news, insider Stefan K.F. Schwabe sold 95,000 shares of the stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $46.59, for a total transaction of $4,426,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $45.23, for a total transaction of $167,758.07. Following the sale, the vice president now owns 17,500 shares of the company’s stock, valued at approximately $791,525. The disclosure for this sale can be found here. Insiders have sold a total of 153,709 shares of company stock valued at $7,223,108 in the last quarter. 6.70% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its position in shares of Supernus Pharmaceuticals by 0.5% during the 2nd quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after purchasing an additional 31,331 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares in the last quarter. State Street Corp increased its position in shares of Supernus Pharmaceuticals by 3.1% during the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after purchasing an additional 42,165 shares in the last quarter. Rice Hall James & Associates LLC increased its position in shares of Supernus Pharmaceuticals by 24.5% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after purchasing an additional 267,971 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Supernus Pharmaceuticals by 10.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock worth $54,654,000 after purchasing an additional 122,042 shares in the last quarter. Institutional investors and hedge funds own 96.11% of the company’s stock.

Supernus Pharmaceuticals (NASDAQ:SUPN) opened at $37.25 on Friday. The company has a market cap of $1,873.63, a PE ratio of 34.48, a PEG ratio of 1.55 and a beta of 1.30. Supernus Pharmaceuticals has a 1-year low of $20.33 and a 1-year high of $50.04. The company has a current ratio of 1.82, a quick ratio of 1.74 and a debt-to-equity ratio of 0.01.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply